Seggewiss Ruth, Dunbar Cynthia E
National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland 20892, USA.
J Clin Invest. 2005 Aug;115(8):2064-7. doi: 10.1172/JCI26041.
Reports of neoplasia related to insertional activation of protooncogenes by retroviral vectors have raised serious safety concerns in the field of gene therapy. Modification of current approaches is urgently required to minimize the deleterious consequences of insertional mutagenesis. In this issue of the JCI, Adjali and colleagues report on their treatment of SCID mice lacking the 70-kDa protein tyrosine kinase, ZAP-70, with direct intrathymic injection of a ZAP-70-expressing T cell-specific lentiviral vector, which resulted in T cell reconstitution. Using lentiviral vectors and in situ gene transfer may represent a safer approach than using retroviral vectors for ex vivo gene transfer into HSCs, avoiding 3 factors potentially linked to leukemogenesis, namely HSC targets, ex vivo transduction and expansion, and standard Moloney leukemia virus-based retroviral vectors.
有关逆转录病毒载体通过原癌基因插入激活导致肿瘤形成的报道,引发了基因治疗领域对安全性的严重担忧。迫切需要对当前方法进行改进,以尽量减少插入诱变的有害后果。在本期《临床研究杂志》中,阿贾利及其同事报告了他们对缺乏70 kDa蛋白酪氨酸激酶ZAP-70的重症联合免疫缺陷(SCID)小鼠进行的治疗,即通过胸腺内直接注射表达ZAP-70的T细胞特异性慢病毒载体,从而实现了T细胞重建。与使用逆转录病毒载体将基因体外导入造血干细胞相比,使用慢病毒载体和原位基因转移可能是一种更安全的方法,可避免可能与白血病发生相关的三个因素,即造血干细胞靶点、体外转导和扩增,以及基于标准莫洛尼白血病病毒的逆转录病毒载体。